Literature DB >> 34663946

Valsartan attenuates cardiac dysfunction and remodelling in patients with HCM.

Karina Huynh1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34663946     DOI: 10.1038/s41569-021-00636-y

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial.

Authors:  Carolyn Y Ho; Sharlene M Day; Anna Axelsson; Mark W Russell; Kenneth Zahka; Harry M Lever; Alexandre C Pereira; Steven D Colan; Renee Margossian; Anne M Murphy; Charles Canter; Richard G Bach; Matthew T Wheeler; Joseph W Rossano; Anjali T Owens; Henning Bundgaard; Lee Benson; Luisa Mestroni; Matthew R G Taylor; Amit R Patel; Ivan Wilmot; Philip Thrush; Jose D Vargas; Jonathan H Soslow; Jason R Becker; Christine E Seidman; Neal K Lakdawala; Allison L Cirino; Kristin M Burns; John J V McMurray; Calum A MacRae; Scott D Solomon; E John Orav; Eugene Braunwald
Journal:  Nat Med       Date:  2021-09-23       Impact factor: 53.440

  1 in total
  1 in total

Review 1.  A narrative review on sacubitril/valsartan and ventricular arrhythmias.

Authors:  Zhaoyang Wei; Meiwei Zhang; Qian Zhang; Linan Gong; Xiangyu Wang; Zanzan Wang; Ming Gao; Zhiguo Zhang
Journal:  Medicine (Baltimore)       Date:  2022-07-08       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.